脑钠肽与心血管疾病

脑钠肽又称B型利钠肽,在心血管疾病的诊断、治疗及预后判断等方面具有重要价值,是临床上与心血管疾病密切相关的一项生化指标.现就脑钠肽的一些生理特性及其在心血管疾病中的研究进展作一综述.     

血浆脑钠肽在急性冠脉综合征患者的变化及与冠脉病变范围的关系

目的探讨血浆脑钠肽（BNP）在急性冠脉综合征（ACS）中的变化及与冠脉病变范围的关系。方法80例经冠状动脉造影证实的ACS患者，其中急性心肌梗死（AMI）患者45例，不稳定型心绞痛（UAP）19例，稳定型心绞痛（SAP）16例，20例冠脉造影阴性者（对照组）。检测AMI患者发病16-20h以及其他研究对象入院时的血浆BNP浓度，比较各组间BNP的差异。结果AMI、UAP、SAP和对照组血浆BNP浓度分别为（504．5±182．1）pg／ml、（248．1±171．7）pg／ml、（39．6±22．9）pg／ml、（21．2±16．0）pg／ml。AMI组平均BNP明显高于UAP组、SAP组和对照组（P〈0．01），UAP组平均BNP明显高于SAP组和对照组（P〈0．01），SAP组高于对照组（P〈0．05）。多支病变组平均BNP高于单支和0支病变组（P〈0．01）。结论不同临床类型冠心病患者的血浆BNP浓度存在差异，其水平高低与冠心病的病变范围关系密切。     

急性冠脉综合征患者血浆脑钠肽水平的变化及其临床意义

目的 探讨急性冠脉综合征（不稳定型心绞痛和急性心肌梗死）血浆脑钠肽（BNP）水平与冠状动脉病变（CAG）严重程度及心功能（左室射血分数LVEF）的关系.方法 以随机抽取的不稳定型心绞痛（UAP）患者89 例和急性心肌梗死（AMI）患者91例作为研究对象,测定其血浆BNP水平,同时检测CAG程度和LVEF,分析血浆BNP水平与CAG程度及心功能之间的相关性.结果 AMI组的血浆BNP水平明显高于UAP组.随着冠状动脉病变支数的增加血浆BNP水平逐渐增高,两者呈正相关（r=0.813,P〈0.01）;随着左室射血分数的降低,血浆BNP水平逐渐升高,两者呈负相关（r=-0.846,P〈0.01）.结论 UAP/AMI患者在发病48 h内血浆BNP水平越高其冠脉病变程度越重,心功能越差.多元逐步回归显示,血浆BNP水平对UAP/AMI患者在发病48 h内的冠脉病变程度及心功能有独立的预测价值.     

老年心力衰竭患者血浆脑钠肽水平与心功能的关系

近年的研究表明,脑钠肽(BNP)是在心室容积扩大和压力负荷增加时,由心室释放的一种心脏神经激素[1,2]。脑钠肽的水平可准确反映左心衰的严重程度,它在许多病理情况下作为一种代偿性机制会有不同程度的升高,尤其是在心力衰竭发生时非常明显[3]。本文旨在探讨脑钠肽水平与老年心力     

动态监测老年糖尿病合并急性冠脉综合征患者血浆脑钠肽变化的意义

目的监测脑钠肽(BNP)浓度,为临床找出早期诊断冠脉综合征(ACS)的可靠标志物。方法在患者发作不稳定性心绞痛(UA)和急性心肌梗死(AMI)后0.5、1、2、3、6、24、48 h,检测其血浆中BNP水平,并以正常人群和稳定性心绞痛患者的血浆BNP含量作为对照,探究BNP在ACS发作后的浓度变化。结果 AMI组的BNP浓度与发病后时间呈正相关(P0.05),UA组的BNP浓度与发病后时间呈正相关(P0.01),UA组、SAP组和正常组的BNP浓度与AMI组的BNP浓度差异显著(P0.05),SAP组和正常组的BNP浓度与前两组的BNP浓度差异显著(P0.05)。结论动态监测BNP浓度可以成为临床早期诊断ACS的有效辅助指标。     

老年心力衰竭患者血浆脑钠肽水平变化及意义

目的探讨老年心力衰竭（心衰）患者血浆脑钠肽（BNP）水平变化的意义。方法采用双抗夹心免疫荧光法检测122例老年心衰患者（观察组）和60例健康者（对照组）血浆BNP水平。结果观察组血浆BNP水平显著高于对照组（P〈0．001）,且随心功能级别增加逐渐增加。结论BNP可用于心衰的早期诊断,能客观反映病情。     

急性冠脉综合征患者测定血浆脑钠肽及C-反应蛋白的意义

目的探讨急性冠脉综合征（ACS）患者血浆脑钠肽（BNP）和C-反应蛋白（CRP）的变化及其临床意义。方法连续选取2009年1月至2010年2月在昆明市第一人民医院住院的ACS患者68例,另选32名同期到院体检的健康者为对照组。两组入选对象均采用电化学发光法检测血浆BNP水平,采用酶联免疫（EuSA）法测定血浆CRP水平。结果ACS组患者血浆BNP及CRP水平均明显高于对照组,各亚组中血浆BNP水平为sT段抬高心肌梗死（STEM!）亚组〉非ST段抬高心肌梗死（NSTEMI）亚组〉不稳定型心绞痛（UAP）亚组〉对照组（992pg／ml〉581pg／ml〉305pg／ml〉48pg／ml,P均〈0．05）。血浆CRP水平为STEMI亚组〉NSTEMI亚组〉UAP亚组〉对照组[（41．2＋7．1）mg／L〉（29．1＋5．0）rag／L〉（14．6＋3．4）mg／L〉（5．5＋2．1）mg／L,P均〈0．05]。血浆BNP与CRP水平呈正相关（r=0．635,P〈0．01）。结论ACS患者血浆BNP和CRP水平明显升高,提示二者在ACS的发病机制中起重要作用。     

脑钠肽在心血管疾病中的应用进展

脑钠肽是一种具有多种生理活性的多肽。可以评判心力衰竭,预测急性冠脉综合征、心力衰竭、心房纤颤患者的预后。此外,对心力衰竭和急性心肌梗死治疗也有显著疗效。     

脑利尿钠肽用于心血管疾病的诊治进展

1981年由de Bold等发现的心房利尿钠肽(ANP)拓展了人们的观念:即心脏不仅是一个机械泵而且还是一个神经内分泌器官.20年来围绕着利尿钠肽家族进行了大量的科学研究,脑利尿钠肽(Brain natriuretic peptide BNP)、C型利钠肽(Ctype natriuretic peptide CNP)及树眼镜蛇利尿钠肽(Dendroaspis natriuretic peptide DNP)相继被发现.     

高敏C反应蛋白、血浆脑钠肽与急性冠脉综合征严重程度的关系

目的探讨急性冠脉综合征（ACS）患者冠状动脉粥样硬化程度与高敏C反应蛋白（hs-CRP）、血浆脑钠肽（BNP）的相关性。方法选择143例冠心病患者分为稳定型心绞痛（SA）组、不稳定型心绞痛（UA）组和急性心肌梗死（AMI）组。采用Leaman积分法评价冠脉病变的严重程度,同时测定患者血浆BNP、hs-CRP水平和左室射血分数（LVEF）,分析血浆BNP、hs-CRP水平与冠心病临床严重程度及冠脉造影Leaman积分之间的关系。结果ACS各组hs-CRP、BNP值、冠脉Leaman积分均显著高于稳定型心绞痛组,ACS各组LVEF低于SA组,AMI组hs-CRP、BNP显著高于不稳定型心绞痛组（P〈0.01）。ACS组血浆BNP水平与LVEF呈负相关（r=-0.499 0,P〈0.01）,与血管病变支数呈正相关（r=0.347 0,P〈0.05）,与冠脉积分呈正相关（r=0.798 4,P〈0.01）。结论ACS患者血浆BNP、hs-CRP与冠脉病变程度存在相关性,BNP、hs-CRP水平可反映心肌受损的程度。     

急性冠状动脉综合征患者血清脑钠肽浓度的变化及临床意义

目的:探讨急性冠状动脉综合征(ACS)患者血清脑钠肽(BNP)水平与其冠状动脉病变严重程度及心脏功能的关系。方法:ACS患者81例,分为不稳定型心绞痛(UAP组)组39例和急性心肌梗死组(AMI)组42例,于入院后即刻检测血清BNP水平,并检查冠状动脉病变情况和左室射血分数,分析BNP的水平与冠状动脉病变、心脏功能之间的关系。结果:血清BNP水平随着病情的加重而逐渐升高,AMI组明显高于UAP组,并且从单支病变、双支病变到3支病变BNP水平逐渐增高,两者呈正相关(rs=0.813,P<0.01);随着左室射血分数的降低,BNP水平逐渐升高,两者呈负相关(rs=-0.846,P<0.01)。结论:血清BNP水平与冠状动脉病变程度及心功能相关,可用于ACS患者的危险评估。     

急性冠状动脉综合征患者血浆脑钠肽和超敏C-反应蛋白的临床分析

目的 探讨急性冠状动脉综合征(ACS)患者血浆脑钠肽(BNP)和超敏C-反应蛋白(hsCRP)的变化及其临床意义.方法 随机选取68例ACS患者,包括不稳定型心绞痛(UAP)32例和急性心肌梗死(AMI)36例,稳定型心绞痛(SAP)组34例,正常对照组30例.采用荧光免疫法测定血浆BNP水平,乳胶增强免疫透射比浊法检测hsCRP的浓度并行超声心动图检查评价室壁运动和心功能.结果 ACS组血浆BNP水平和hsCRP水平与SAP组和对照组比较显著升高(P<0.01).多支血管病变患者BNP和hsCRP水平显著高于单支血管病变者.在ACS患者中,左室射血分数(LVEF)减低(LVEF<50%)的患者血浆BNP水平明显高于LVEF正常(LVEF≥50%)的患者(P<0.01).ACS组血浆BNP和hsCRP水平呈正相关(r＝0.5387,P<0.01).结论 血浆BNP和hsCRP水平在ACS患者中显著升高,血浆BNP的升高水平与LVEF异常明显相关.检测血浆BNP和hsCRP水平对ACS的辅助诊断、疗效观察及预后判断具有重要价值.     

急性心肌缺血是血脑钠素水平升高的独立因素

目的 探讨急性心肌缺血是否引起血浆脑钠素(brain natriuretic peptide,BNP)水平升高.方法 回顾性分析冠心病无心力衰竭病人168例血浆BNP浓度.其中稳定型心绞痛组40例,不稳定型心绞痛组23例,急性心肌梗死组105例.另外,健康体检者为对照组88例.BNP测定采用酶联免疫吸附试验方法.结果 稳定型心绞痛组血浆BNP浓度中位数42.3(7.6～491.3)ng/L,与正常对照组25.9(5.1～87.9)ng/L相比,差异有统计学意义(P=0.001).不稳定型心绞痛组血浆BNP水平142.4(92.4～2617.7)ng/L,急性心肌梗死组126.0(5.5～3615.1)ng/L,均显著高于对照组(P=0.000)和稳定型心绞痛组(P=0.000).不稳定型心绞痛组BNP水平显著高于急性心肌梗死组(P=0.04).结论 急性心肌缺血是血浆BNP水平升高的重要原因之一,血浆BNP水平检测可能有助于甄别急性冠状动脉综合征与稳定型冠心病.     

脑钠肽与急性冠状动脉综合征关系的研究

目的探讨脑钠肽（BNP）与急性冠状动脉综合征（ACS）的关系。方法将115例入院患者行冠状动脉造影后分为4组：稳定型心绞痛组（SAP）24例,不稳定型心绞痛组（UAP）35例,急性心肌梗死组（AMI）28例,冠状动脉造影无狭窄或狭窄〈25％者为对照组28例。测定其外周静脉血脑钠肽（BNP）水平和超敏C反应蛋白（hs—CRP）水平,分析各组BNP水平之间的关系,以及Gensim积分和hs—CRP水平与其相应的BNP水平的关系。结果①UAP组、AMI组血浆BNP浓度较对照组、SAP组明显升高[（82．78±14．15）μg／L、（91．87±17．00）μg／L比（41．93±6．34）Dg／L、（45．52±6．65）μg／L],且差异有统计学意义（P〈0．05）;SAP组血浆BNP浓度较对照组升高[（45．52±6．65）μg/L比（41．93±6．34）μg／L],但差异无统计学意义（P〉0．05）;AMI组血浆BNP浓度较UAP组升高[（91．87±17．00）μg／L比（82．78±14．15）μg/L],但差异无统计学意义（P〉0．05）。②血浆BNP浓度与其相应的Gensim积分呈明显正相关（r=0．331,P〈0．05）。③血浆BNP浓度与其相应的hs—CRP水平呈明显正相关（r=0．475,P〈0．05）。结论血浆BNP浓度可能作为预测急性冠脉综合征危险分层和判断预后的参考指标之一。     

脑钠肽对急性冠状动脉综合征近期预后的评价

目的:探讨脑钠肽(BNP)对急性冠状动脉综合征(ACS)近期预后评价的价值。方法:使用 TriageBNP干氏床旁快速检测方法对106例ACS患者入院1~3 d的 BNP水平进行测量,随访 1 个月,分为存活组和死亡组。结果:①存活组和死亡组 BNP水平差异有统计学意义(P<0.01); ②单因素分析表明:血 BNP≥172ng/L(中位数)和Killip分级Ⅱ级以上为1个月内心源性死亡的预测因素(均 P<0.01 );③Logistic回归分析表明:吸烟和血BNP≥596 ng/L(75%百分位数)为1个月内心源性死亡的独立预测因素(OR=5.50,P<0.05;OR=21.19,P<0.01)。结论:ACS患者血BNP水平与其近期预后相关。     

Value of N-terminal pro brain natriuretic peptide in predicting prognosis and severity of coronary artery disease in acute coronary syndrome

Background

Measurement of N-terminal pro brain natriuretic peptide (NT-proBNP) in the evaluation of patients with acute coronary syndrome has appeared to be a useful prognostic marker of cardiovascular risk.

Aim of the work

To assess the in-hospital prognostic value of NT-proBNP in patients with acute coronary syndrome (ACS) and its relation to the severity of coronary artery disease.

Patients and methods

This study included 132 consecutive patients with ACS, 64 patients with unstable angina (UA), 46 patients with non-ST segment elevation myocardial infarction (NSTEMI), and 22 patients with ST segment elevation myocardial infarction (STEMI). ECG, echocardiography and pre and post coronary angiography measurement of troponin I, creatine kinase (Ck), C-reactive protein (CRP) and NT-proBNP were done. Patients were divided into two groups: Group A with NT-proBNP less than 474 pg/ml and Group B with NT-proBNP equal or more than 474 pg/ml.

Results

There was a significant negative correlation between NT-proBNP and ejection fraction. Incidence of heart failure and duration of hospital stay were significantly higher in Group B (with NT-proBNP equal or more than 474 pg/ml) than Group A (with NT-proBNP less than 474 pg/ml). Moreover, there was a trend to an increased incidence of cardiogenic shock and mortality in Group B compared to Group A. The number of coronary vessels affected, severity of stenosis and proximal left anterior descending artery (LAD) disease were higher in Group B than in Group A. TIMI flow grade was significantly higher in Group A than in Group B.

Conclusion

NT-proBNP is a valuable marker for predicting prognosis and severity of coronary artery disease in patients with acute coronary syndrome.     

老年冠心病患者择期介入治疗对血浆B型钠尿肽的影响

目的探讨血浆B型钠尿肽(BNP)水平与老年冠心病择期PCI患者的关系。方法选择行择期PCI的冠心病患者284例,根据病变分为单支病变组109例、双支病变组99例、多支病变组76例。分别检测患者PCI术前及术后7 d BNP、肌钙蛋白I(cTnI)和LVEF,同时分析PCI术前、术后BNP水平与冠状动脉病变的关系。结果与单支病变组比较,双支和多支病变组患者BNP和cTnI水平升高,3组两两比较,差异有统计学意义(P<0.01)。3组择期PCI术后BNP水平较术前降低,差异均有统计学意义(P<0.01),而择期PCI前后cTnI、LVEF差异无统计学意义(P>0.05)。结论老年冠心病患者行择期PCI可改善心肌缺血,降低BNP水平。BNP水平可作为判断心肌缺血的临床指标之一。     

N-terminal pro B-type natriuretic peptide identifies patients with chest pain at high long-term cardiovascular risk

Background

Little is known about the long-term prognostic value of N-terminal pro B-type natriuretic peptide (NT-proBNP) and C-reactive protein (CRP) in low-risk patients with chest pain.

Methods

Between June 1997 and January 2000, a standard rule-out protocol was performed in patients presenting to the emergency department within 6 hours of onset of chest pain with a normal or nondiagnostic electrocardiogram (ECG) on admission at the Academic Medical Center Amsterdam, VU University Medical Center Amsterdam and Medical Center Alkmaar, The Netherlands. Patients with acute coronary syndrome were identified by troponin T, recurrent angina, and serial ECGs. CRP and NT-proBNP on admission were measured using standardized methods.

Results

A total of 524 patients were included (145 with acute coronary syndrome and 379 with rule-out acute coronary syndrome). Long-term follow-up was successfully carried out in 96% of the study population. Death occurred in 78 patients (15%), 43 (11%) in the rule-out acute coronary syndrome group and 35 (24%) in the acute coronary syndrome group (P < .001). In the rule-out acute coronary syndrome group, 21 patients (42%) died of a cardiovascular cause compared with 24 patients (69%) in the acute coronary syndrome group (P < .001). In multivariate Cox regression analysis, age more than 65 years, previous myocardial infarction, known chronic heart failure, a nondiagnostic ECG on admission, and elevated NT-proBNP levels (>87 pg/mL, as derived from the receiver operating characteristic curve) were independent predictors of long-term cardiovascular mortality in the rule-out acute coronary syndrome group. In the acute coronary syndrome group, these predictors were age more than 65 years, documented coronary artery disease, and elevated NT-proBNP levels. Elevated levels of CRP were an independent predictor for cardiovascular mortality in patients with rule-out acute coronary syndrome at 3-year follow-up only. In patients with rule-out acute coronary syndrome with normal CRP and NT-proBNP levels, the cardiovascular mortality incidence rate was 4.7 per 1000 person-years, compared with a death rate of 20 in patients with both biomarkers elevated, which was comparable to the 17.9 per 1000 person-years incidence rate in patients with acute coronary syndrome.

Conclusion

A positive biomarker panel discriminates patients with rule-out acute coronary syndrome chest pain with a normal or nondiagnostic ECG who have a high risk for long-term cardiovascular mortality.